Viridian Therapeutics, Inc.\DE (VRDN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $21.05, Viridian Therapeutics, Inc.\DE (VRDN) is priced for today's economics sustained for ~18.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/VRDN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 9.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.6 years.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=6)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Viridian just crossed the line from clinical-stage biotech to commercial company: on June 25, 2026 the FDA approved Lumvoa (veligrotug), its IV antibody for thyroid eye disease, and the company began launching immediately to a target of about 2,000 core prescribers.

• The prize is Amgen's Tepezza market, which generated about $1.9 billion last year. Viridian's Phase 3 data showed a placebo-adjusted proptosis resolution rate of 43% against the 28% reported in the Tepezza studies, and a subcutaneous follow-on, elegrobart, is in Phase 3 with a filing targeted for early 2027.

• The valuation is a launch bet the standard frames cannot support. At $16.66 the company is unprofitable and priced against sales, so the X-ray puts every method below the price. The cushion is a strong balance sheet, roughly $762 million in cash, enough to fund the launch and the pipeline toward profitability.

Bull Case

The clearest way to see the bull case is how far the price sits above the static valuation methods, and why that is the wrong way to judge a company at this exact moment. Viridian is unprofitable, so the X-ray has no earnings family and the asset and peer-multiple frames land well below the price; on paper, no standard method reaches $16.66 (June 28, 2026). But those methods are reading a company that, as of June 25, 2026, just stopped being pre-revenue. The FDA approved Lumvoa, veligrotug, for thyroid eye disease, Viridian's first commercial product, and the company is launching it now. The single biggest risk in a clinical biotech, regulatory approval, has been removed, and the valuation methods have not yet caught up to a business that is about to generate real sales.

The commercial opportunity is large and contested by a product Viridian's data suggest it can beat. Thyroid eye disease is currently served by Amgen's Tepezza, which generated about $1.9 billion last year as the only approved therapy. Viridian's Phase 3 program, THRIVE and THRIVE-2, delivered strong results: roughly 70% of veligrotug recipients achieved at least a 2 mm reduction in proptosis after five infusions over fifteen weeks, and the placebo-adjusted resolution rate was 43%, ahead of the 28% reported in the Tepezza studies. Better efficacy on the headline endpoint, in a market that has demonstrated nearly $2 billion of demand, is the foundation of a credible second entrant.

The pipeline and the balance sheet extend the story past the first launch. Viridian is advancing elegrobart, VRDN-003, a subcutaneous, self-administered version designed for less frequent and more convenient dosing, with a Phase 3 program, REVEAL-1 and REVEAL-2, the latter already positive, and a filing targeted for early 2027. A convenient, at-home subcutaneous option could expand the treated population well beyond the infusion-clinic setting. Funding it is not the problem: the company held roughly $762 million in cash and short-term investments at the end of the first quarter, which management has described as sufficient to carry operations to profitability. The analyst consensus is a buy with an average target in the high thirties to low forties, well above the current price. The bull case is a freshly approved, best-in-class-data drug launching into a $1.9 billion market, with a subcutaneous follow-on and the cash to fund both.

Bear Case

The disruption risk runs both ways, and Viridian is the challenger walking into an entrenched incumbent's market. Tepezza is Amgen's established product with years of physician familiarity, payer relationships, and a sales infrastructure that a newly commercial company has to build from scratch against a target of about 2,000 prescribers. Better trial data does not automatically translate into prescriptions: formulary access, prior-authorization hurdles, infusion-site economics, and the simple inertia of physicians who already know how to use Tepezza all stand between approval and revenue. Amgen is not standing still either, having advanced its own more convenient on-body injected version of Tepezza, which directly attacks the convenience advantage Viridian is counting on with elegrobart. A second mover whose main edge is data and dosing can find both eroded by an incumbent with deeper pockets.

The financial profile is the structural fragility. Viridian is deeply unprofitable, with a trailing operating loss in the hundreds of millions and an operating margin that is meaningless to quote because there is essentially no revenue base yet. A drug launch is expensive: building a commercial organization, manufacturing at scale, and supporting two ongoing Phase 3 programs all consume cash. The roughly $762 million on hand is a genuine cushion, but launches routinely cost more and take longer than planned, and if Lumvoa uptake is slow the company could face the choice between scaling back or returning to the equity market. Share count has already grown sharply with prior financings, so further dilution is a live risk for existing holders.

Finally, the price already discounts a successful launch, which leaves little room for a stumble. The stock is valued against sales at a high multiple, and the implied path requires the business to reach a healthy operating margin and grow for many years; no valuation family supports the current price on present fundamentals. For a single-market, single-mechanism company, the concentration is acute: the entire thesis rests on TED, on IGF-1R antibodies, and now on out-launching Amgen. A disappointing early sales ramp, a competitive label or dosing advantage from Amgen's next-generation Tepezza, or a setback in the elegrobart program would each strike at the core of the story, and a richly priced biotech with no diversification has a long way to fall when a binary goes the wrong way.

Valuation

Viridian is not yet earning an operating profit, so the price is set against sales, and the result is a forward bet rather than a value calculation. At $16.66 the stock trades at roughly 14 times revenue, and the inversion shows the price implies the business eventually earns an operating margin around 23% and grows at its self-funding ceiling for about twelve years. Those figures carry low reliability and should be read as the shape of the bet, not a measurement: the market is paying today for a commercial trajectory that has barely begun. The two operating-income bases diverge by more than 100%, a reminder of how early and noisy the financials are.

The X-ray is unambiguous about the character of the price. With no earnings to anchor on, the earnings family is empty, the asset-based and relative-multiple families land well below the price, and even the forward-growth family does not reach it. On every standard frame the stock looks expensive. That is normal and expected for a biotech at the launch of its first product: the value is in the approved drug and the pipeline, not in trailing statements, and conventional methods systematically understate a company at this inflection.

The reference point that matters is the $1.9 billion Tepezza market and Viridian's superior trial data, set against the cost and uncertainty of taking share from an entrenched incumbent. The roughly $762 million cash balance, described as enough to fund operations to profitability, materially reduces the financing risk that sinks many biotechs. The analyst targets in the high thirties to low forties price in a successful launch and a credible elegrobart follow-on. The conclusion is that the valuation only makes sense if Lumvoa ramps and the subcutaneous program advances; the upside is in execution, and the downside if the launch disappoints is severe because nothing in the current numbers supports the price.

Catalysts

The defining catalyst already landed: on June 25, 2026 the FDA approved Lumvoa (veligrotug) for thyroid eye disease, Viridian's first commercial product, and the company began launching immediately to a target of about 2,000 core prescribers. From here the catalyst becomes the launch curve itself, the first quarters of prescriptions, payer coverage, and the pace of uptake against Amgen's established Tepezza, which is the single most important data the market will watch.

The pipeline provides the next milestone. Elegrobart (VRDN-003), the subcutaneous, self-administered version designed for more convenient dosing, is in Phase 3 with REVEAL-2 already positive and a biologics license application targeted for early 2027. Progress in REVEAL-1 and the filing timeline are the key checkpoints, since a convenient at-home option could materially expand the addressable population.

The competitive and financial threads frame the rest. Amgen is advancing an on-body injected version of Tepezza that targets the same convenience advantage, so any data or approval there is a direct catalyst for Viridian. On the balance sheet, the roughly $762 million cash position funds the launch and the pipeline, but the cash-burn rate and any need to raise capital are recurring swing factors. The analyst consensus is a buy with an average target in the high thirties to low forties, so a successful early launch is what would move sentiment and close the gap to those targets.

Peer Cohorts (Per Segment, With Filing Citations)

Biopharmaceutical R&D (whole-company) (reported)

• CRNX (Crinetics Pharmaceuticals, Inc.)
• FY2025 10-K: …allocating resources, assessing performance and monitoring budget versus actuals. The Company's CODM is its founder and Chief Executive Officer. The Company operates as a single operating and reportable segment, focused on the discovery, development, and commercialization of therapeutics for rare endocrine diseases…
• FY2025 10-K: …costs incurred for approved products, where activities relate to commercialization rather than research and development. Research and Development Expenses Research and development ("R&D") expenses consist of personnel-related costs, including salaries, benefits, payroll taxes, and stock-based compensation for…
• IMCR (Immunocore Holdings plc)
• FY2025 10-K: …medicines in the areas of cancer, infectious diseases and autoimmune diseases. The Company primarily generates revenue from one stream, revenue from the sale of therapies, which consists of sales of KIMMTRAK . H istorically, the Company had a second stream, collaboration revenue, which is no longer significant. The…
• FY2025 10-K: Company and will mature on February 1, 2030, unless earlier converted, redeemed or repurchased. The Notes will accrue interest payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024, at a rate of 2.50% per year. See Note 7. "Interest-bearing loans and borrowings" of the…
• RYTM (RHYTHM PHARMACEUTICALS, INC.)
• FY2025 10-K: …trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Commercialization of…
• FY2025 10-K: …and related notes appearing elsewhere in this Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as…
• ARQT (ARCUTIS BIOTHERAPEUTICS, INC.)
• FY2025 10-K: …the wholesaler and the wholesaler's customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are…
• FY2025 10-K: …studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug's approval. Five year and three year exclusivity will not delay the submission or…
• OCUL (Ocular Therapeutix, Inc.)
• FY2025 10-K: …about the Company's single segment: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Revenue ​ $ 51,951 ​ $ 63,723 ​ $ 58,443 Cost of Product Revenue ​ ​ 6,574 ​ ​ 5,626 ​ ​ 5,281 Research & Development (a) ​ ​ ​ ​ ​ ​ ​ ​ ​ Direct Program Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​…
• FY2025 10-K: …and stock-based compensation expense for employees engaged in research and development, clinical and regulatory and other related functions; ● expenses relating to regulatory activities, including filing fees paid to the FDA for our submissions for product approvals; ● expenses associated with developing our…
• LQDA (LIQUIDIA CORPORATION)
• FY2025 10-K: …new skilled personnel. Our ability to continue our operations and manage our potential future growth depends on our ability to hire and retain suitably skilled and qualified employees, including those in senior management, in the long-term. Due to the specialized nature of our work, there is a limited supply of…
• FY2025 10-K: …action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption of the generic product and the reference listed drug. For some drugs, including locally acting drugs such as topical anti-fungals, other means of demonstrating bioequivalence may be…
• NUVB (Nuvation Bio Inc.)
• FY2025 10-K: …that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of 12 cancer therapies. Any investigational products that we successfully develop and commercialize will compete with new therapies that may become available in the…
• FY2025 10-K: …can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and trial activities of the Company's products, the Company's ability to obtain and maintain regulatory approval to market its products, competition from…
• STOK (Stoke Therapeutics, Inc.)
• FY2025 10-K: …of future net sales on the licensed products. As of December 31, 2025, no milestones have been met. Royalties payable under the Biogen Agreement are subject to standard royalty reductions. For the year ended, December 31, 2025, we recognized revenue related to the Biogen collaboration of $168.3 million; there was no…
• FY2025 10-K: (k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers all employees who meet defined minimum age and service requirements 120 and allows participants to defer a portion of their annual compensation on a pretax basis. The Company matches contributions up to 4 % of annual salary for those…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.